Receptor occupancy of mirtazapine determined by PET in healthy volunteers

Psychopharmacology

Volumn 195, Issue 1, 2007, Pages 131-138

  Smith, Donald F ^a   Stork, Bo S ^a   Wegener, Gregers ^a   Jakobsen, Steen ^b   Bender, Dirk ^b   Audrain, Hélène ^b   Jensen, Svend B ^b   Hansen, Søren B ^b   Rodell, Anders ^b   Rosenberg, Raben ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anti depressant; Binding potential; Mirtazapine; PET; Receptor occupancy

Indexed keywords

MIRTAZAPINE; MIRTAZAPINE C 11; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; BINDING KINETICS; BRAIN CORTEX; BRAIN REGION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG BLOOD LEVEL; FATIGUE; FEMALE; HIPPOCAMPUS; HUMAN; IRRITABILITY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; SIDE EFFECT; VOLUNTEER;

ADULT; AMYGDALA; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BRAIN; CARBON RADIOISOTOPES; CEREBELLUM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HIPPOCAMPUS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIANSERIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTORS, CELL SURFACE; TABLETS; TIME FACTORS; TRIMIPRAMINE;

EID: 35248852880     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-007-0877-x     Document Type: Article

References (48)

1. Adams KH, Pinborg LH, Svarer C, Hasselbalch SG, Holm S, Haugbol S, Madsen K, Frokjaer V, Martiny L, Paulson OB, Knudsen GM (2004) A database of [18F]-altanserin binding to 5-HT2A receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage 21:1105-1113
2. Aldrich MS, Prokopowicz G, Ockert K, Hollingsworth Z, Penney JB, Albin RL (1994) Neurochemical studies of human narcolepsy: alpha-adrenergic receptor autoradiography of human narcoleptic brain and brainstem. Sleep 17:598-608
3. Brunello N, Blier P, Judd LL, Mendlewicz J, Nelson CJ, Souery D, Zohar J, Racagni G (2003) Noradrenaline in mood and anxiety disorders: basic and clinical studies. Int Clin Psychopharmacol 18:191-202
4. Collins DL, Neelin P, Peter TM, Evans AC (1994) Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr 18:192-205
5. de Boer T (1996) The pharmacologic profile of mirtazapine. J Clin Psychiatry 57(Suppl 4):19-25
6. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM (1988) Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 27:399-408
7. De Vos H, Bricca G, De Keyser J, De Backer JP, Bousquet P, Vauquelin G (1994) Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha2-adrenoceptors in the human central nervous system. Neuroscience 59:589-598
8. Drevets WC (2000) Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Prog Brain Res 126:413-431
9. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538-544
10. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M (2001) Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 62:413-420
11. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH (2006) A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. Am J Psychiatry 163:1161-1172
12. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198
13. Grasby PM (1999) Imaging strategies in depression. J Psychopharmacol 13:346-351
14. Holmberg M, Fagerholm V, Scheinin M (2003) Regional distribution of alpha(2C)-adrenoceptors in brain and spinal cord of control mice and transgenic mice overexpressing the alpha2C-subtype: an autoradiographic study with [3H]RX821002 and [3H]rauwolscine. Neuroscience 117:875-898
15. Jakobsen S, Pedersen K, Smith DF, Jensen SB, Munk OL, Cumming P (2006) Detection of alpha2-adrenergic receptors in brain of living pig with 11C-Yohimbine. J Nucl Med 47:2008-2015
16. Kabani N, MacDonald D, Holmes C, Evans AC 3D Atlas of the human brain.(1998) Fourth International Conference on Functional Mapping of the Human Brain, Montreal, Quebec, Canada
17. Kent JM (2003) SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355:911-918
18. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
19. Laruelle M, Slifstein M, Huang Y (2002) Positron emission tomography: imaging and quantification of neurotransporter availability. Methods 27:287-299
20. Lundberg J, Christophersen JS, Petersen KB, Loft H, Halldin C, Farde L (2007) PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 1-9
21. Marthi K, Bender D, Gjedde A, Smith D (2002a) [11C]Mirtazapine for PET neuroimaging: radiosynthesis and initial evaluation in the living porcine brain. Eur Neuropsychopharmacol 12:427-432
22. Marthi K, Bender D, Watanabe H, Smith DF (2002b) PET evaluation of a tetracyclic, atypical antidepressant, [N-methyl-11C]mianserin, in the living porcine brain. Nucl Med Biol 29:317-319
23. Marthi K, Hansen SB, Jakobsen S, Bender D, Smith SB, Smith DF (2003) Biodistribution and radiation dosimetry of [N-methyl-11C]mirtazapine, an antidepressant affecting adrenoceptors. Applied Radiation and Isotopes 59:175-179
24. Marthi K, Jakobsen S, Bender D, Hansen SB, Smith SB, Hermansen F, Rosenberg R, Smith DF (2004) [N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. Psychopharmacology (Berl) 174:260-265
25. Mayberg H (2002) Depression, II: localization of pathophysiology. Am J Psychiatry 159:1979
26. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ (2006) Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry163:1531-1541
27. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S (2001) Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am J Psychiatry158:1843-1849
28. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry161:826-835
29. Millan MJ (2006) Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110:135-370
30. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F (2000) Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci 12:1079-1095
31. Reis M, Prochazka J, Sitsen A, Ahlner J, Bengtsson F (2005) Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study. Ther Drug Monit 27:469-477
32. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S (2006) A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry163:396-401
33. Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z, Rafi-Tari S (2004) Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 22:409-418
34. Smith DF, Dyve S, Minuzzi L, Jakobsen S, Munk OL, Marthi K, Cumming P (2006) Inhibition of [11C]mirtazapine binding by alpha2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain. Synapse 59:463-471
35. Stahl SM (2006) Essential Psychopharmacology. The Prescriber's Guide. Cambridge University Press, New York, NY
36. Stimmel GL, Dopheide JA, Stahl SM (1997) Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 17:10-21
37. Strazielle C, Lalonde R, Hebert C, Reader TA (1999) Regional brain distribution of noradrenaline uptake sites, and of alpha1-alpha2- and beta-adrenergic receptors in PCD mutant mice: a quantitative autoradiographic study. Neuroscience 94:287-304
38. Szegedi A, Schwertfeger N (2005) Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother 6:631-641
39. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S, Ido T, Itoh M, Sasaki H, Watanabe T, Yanai K (2001) Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol 52:501-509
40. Talairach P, Tournoux P (1988) Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional system: An Approach to Cerebral Imaging. Georg Thieme, Stuttgart
41. Talbot PS, Laruelle M (2002) The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. Eur Neuropsychopharmacol 12:503-511
42. Timmer CJ, Paanakker JE, van Hal HJM (1996) Pharmacokinetics of mirtazapine from orally administered tablets: influence of gender, age and treatment regimen. Human Psychopharmacology 11:497-509
43. Timmer CJ, Sitsen JM, Delbressine LP (2000) Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461-474
44. Versiani M, Moreno R, Ramakers-van Moorsel CJ, Schutte AJ (2005) Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 19:137-146
45. Videbech P, Ravnkilde B, Pedersen AR, Egander A, Landbo B, Rasmussen NA, Andersen F, Stodkilde-Jorgensen H, Gjedde A, Rosenberg R (2001) The Danish PET/depression project: PET findings in patients with major depression. Psychol Med 31:1147-1158
46. Wilson AA, Johnson DP, Mozley D, Hussey D, Ginovart N, Nobrega J, Garcia A, Meyer J, Houle S (2003) Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter. Nucl Med Biol 30:85-92
47. Yasuno F, Hasnine AH, Suhara T, Ichimiya T, Sudo Y, Inoue M, Takano A, Ou T, Ando T, Toyama H (2002) Template-based method for multiple volumes of interest of human brain PET images. Neuroimage 16:577-586
48. Zilles K, Qu M, Schleicher A (1993) Regional distribution and heterogeneity of alpha-adrenoceptors in the rat and human central nervous system. J Hirnforsch 34:123-132